The U.K.'s main pharma R&D lobby group has hit the national front pages today over threats the industry could start to leave the country.

French pharma Onxeo is teaming up with CRO Clinigen to bring blood cancer med belinostat to European patients in dire need through a managed access program.

Intuitive Surgical has bagged a CE mark for the latest product in its da Vinci series of robot-assisted surgical systems.

Infectious disease specialist Arsanis has raised a solid chunk of cash as it picks up the Gates Foundation and Alphabet's GV as backers.

AstraZeneca has taken another step toward the completion of its new headquarters and R&D hub in Cambridge, U.K.

Amgen has firmed up its lead in the race to bring the first CGRP inhibitor to market for migraine after presenting positive results from its two phase 3 trials.

Otsuka Pharmaceutical has expanded its anemia pact with Akebia Therapeutics.

The FDA granted Allergan marketing authorization for its intranasal tear stimulator, which temporarily increases tear production in adult patients.

Novartis will play a bigger role in the marketing of Amgen's migraine drug erenumab, and analysts say the move may reflect reduced sales expectations.